Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT

RCT (n=544) reports decline in standardised MMSE scores over the 24-month study period in the combined minocycline arms was similar to that in the placebo arm (4.1- vs. 4.3-point reduction; p = 0.9), whilst more patients on minocycline reported serious adverse effects.


National Institute for Health Research